Raymond James Financial Inc. Makes New $208,000 Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Raymond James Financial Inc. bought a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 135,722 shares of the biotechnology company's stock, valued at approximately $208,000. Raymond James Financial Inc. owned 0.09% of Heron Therapeutics as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Heron Therapeutics by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after acquiring an additional 154,487 shares during the period. Principal Financial Group Inc. grew its holdings in Heron Therapeutics by 10.6% during the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 10,909 shares during the period. Wells Fargo & Company MN grew its holdings in Heron Therapeutics by 22.2% during the fourth quarter. Wells Fargo & Company MN now owns 74,763 shares of the biotechnology company's stock worth $114,000 after acquiring an additional 13,568 shares during the period. Congress Park Capital LLC grew its holdings in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after acquiring an additional 477,417 shares during the period. Finally, Barclays PLC grew its holdings in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after acquiring an additional 50,109 shares during the period. 80.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HRTX has been the topic of a number of analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com cut Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Stock Performance

HRTX traded up $0.10 during trading on Friday, reaching $1.97. The company had a trading volume of 1,254,610 shares, compared to its average volume of 2,320,510. The firm's 50-day simple moving average is $2.14 and its 200 day simple moving average is $1.82. The company has a market cap of $300.55 million, a price-to-earnings ratio of -10.94 and a beta of 1.33. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analysts' expectations of $37.08 million. On average, sell-side analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.